Inhibitory effect of farnesylthiosalicylic acid on mediators release by mast cells: preferential inhibition of prostaglandin D(2) and tumor necrosis factor-α release.
There is substantial evidence suggesting that the Ras inhibitor farnesylthiosalicylic acid (FTS) may modulate various aspects of immune function and inflammation in addition to its well known anti-cancer activity. In this regard, we have recently shown that FTS suppresses T lymphocyte-mediated immune responses. Mast cells (MC), the main effector cells in the elicitation of the allergic response, are known to secrete granule-associated mediators and to release prostaglandins and cytokines on FCεRI-cross-linking, thereby contributing to the pathogenesis of allergic diseases. We hypothesized that MC act as an additional target for FTS. In the present work we analyze the effects of FTS on MC degranulation, prostaglandin release, and cytokine release in vitro, and on the elicitation of IgE-mediated MC dependent cutaneous allergic inflammation in vivo. First we have established that FTS inhibited Ras activation in MC. Next, we have shown that FTS preferentially inhibited prostaglandin (PG) D(2) and tumor necrosis factor (TNF)-α release without having any significant effect on MC β-hexosaminidase secretion. In vivo administration of FTS inhibited the late phase of passive cutaneous anaphylaxis reaction. The time course of FTS-induced inhibition in vivo correlated with mediators release and not with degranulation. This data suggests that FTS may have an inhibitory effect on MC mediated allergic inflammation, and thus may be considered as a possible therapeutic modality.
Mor
Adam
A
Department of Neurobiology, The George Weise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, 61390, Israel. Adam.Mor@NYUMC.org
Ben-Moshe
Ofer
O
Mekori
Yoseph A
YA
Kloog
Yoel
Y
D000818:Animals; D015550:Cell Degranulation / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D005204:Farnesol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006801:Humans; D008407:Mast Cells / Q000187:drug effects* / Q000276:immunology / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects / Q000276:immunology / Q000502:physiology; D015230:Prostaglandin D2 / Q000378:metabolism*; D012459:Salicylates / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D018631:ras Proteins / Q000378:metabolism
D012459:Salicylates; D014409:Tumor Necrosis Factor-alpha; C093323:farnesylthiosalicylic acid; D005204:Farnesol; D018631:ras Proteins; D015230:Prostaglandin D2